Skip to search formSkip to main contentSkip to account menu

SB939

Known as: HDAC Inhibitor SB939 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

pracinostat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia
Chronic myeloid leukemia (CML) treatment has been improved by tyrosine kinase inhibitors (TKIs) such as imatinib mesylate (IM… 
2017
2017
Targeting Histone Deacetylase in Renal Tubular Epithelial Cells Inhibits Amplification of TH1 Cell-Mediated Inflammation
Background More studies are focusing on renal tubular epithelial cells (RTECs) as a new target to restore inflammatory… 
2016
2016
Phase I study of SB939 three times weekly for 3 weeks every 4 weeks in patients with advanced solid malignancies.
2560 Background: SB939 is a novel orally bioavailable inhibitor of class 1 and 2 histone deacetylases. We conducted a phase I… 
2014
2014
Multiple Oral Therapeutics Suppress Repressors (LSD-1, HDACs, and BCL11A) of Gamma Globin Gene Expression
Induction of gamma globin expression to certain target levels reduces clinical severity in sickle cell disease, globin imbalance… 
2012
2012
Histone Deacetylase Inhibitor SB 939 Antimalarial Activity of the Anticancer
2011
2011
Therapy with the Histone Deacetylase Inhibitor Sb939 for Patients with Myelofibrosis
Abstract 3863 Background: The discovery of the JAK2V617F mutation has triggered the development of agents that target the… 
2010
2010
Abstract 5436: The histone deacetylase inhibitor SB939 acts synergistically with Sorafenib in an orthotopic model of hepatucellular carcinoma
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Introduction: SB939 is an hydroxamic acid based… 
2008
2008
83 POSTER A robust and quantitative biomarker assay for SB939, a potent, orally-active HDAC inhibitor
2006
2006
162 POSTER Pharmacological profile of SB939, a novel, potent and orally active histone deacetylase inhibitor
2006
2006
166 POSTER ADME and PK/PD attributes of SB939, a potent orally active HDAC inhibitor
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)